Browse by Series:

OncLive News Network On Location: GU 2020 Day 3

Published: Saturday, Feb 15, 2020



Today-

We are on site at the Moscone Center in San Francisco, California at the 2020 Genitourinary Cancers Symposium!

We have recapped some of the top news presented each day during the meeting—and soon we’ll speak with Dr Daniel Petrylak on the key studies in bladder cancer and prostate cancer, as well as Dr Brian Rini on the latest in kidney cancer.

Welcome to OncLive News Network! I’m Gina Columbus.

In advanced clear cell renal cell carcinoma, the oral HIF-2 alpha inhibitor MK-6482 demonstrated promising clinical activity in heavily pretreated patients in a phase I/II trial.

Results showed that the objective response rate with MK-6482 was 24%, with 69% of patients experiencing tumor shrinkage. Moreover, the median progression-free survival was 11.0 months. The agent was also found to be well tolerated. Based on these encouraging data, there are plans to launch a phase III trial with MK-6482.

The combination of the RTK inhibitor sitravatinib and nivolumab showed a benefit in patients with advanced clear cell renal cell carcinoma following progression on prior VEGF-targeted therapy.

Specifically, results showed that there were higher objective responses and longer disease control versus what is historically expected with single-agent nivolumab in this patient population.

The first results of the phase II NIVES trial showed that nivolumab in combination with stereotactic body radiotherapy led to a high disease control rate in pretreated patients with metastatic renal cell carcinoma.

The regimen also led to no added toxicity, and an analysis is ongoing to explore the correlation between efficacy of the combination and PD-L1 expression.

Real-world results of the Meet-Uro 7 study showed that following progression on immunotherapy, most patients were treated with VEGF-TKI therapy and mTOR inhibitors, which were found to be both active and safe. Specifically, the multikinase TKI cabozantinib was found to be associated with a longer modified progression-free survival.

In the retrospective study, investigators evaluated outcome data, including PFS and toxicities, from 162 eligible patients who were treated across 16 Italian referral centers.

Forty-two month follow-up of the phase III CheckMate-214 trial showed that the combination of nivolumab and ipilimumab showed superior objective response rates and overall survival compared with sunitinib in both intent-to-treat and intermediate and poor-risk patients with advanced renal cell carcinoma.

Additionally, more patients who were treated with nivolumab and ipilimumab experienced a complete response versus sunitinib. Based on earlier data from the CheckMate-214 trial, the FDA approved this combination in April 2018 for intermediate- and poor-risk patients with advanced renal cell carcinoma.

That’s all for today. Thank you for watching OncLive News Network: On Location at the 2020 Genitourinary Cancers Symposium.

Signing off from San Francisco, California, I’m Gina Columbus.
SELECTED
LANGUAGE
Slider Left
Slider Right


Today-

We are on site at the Moscone Center in San Francisco, California at the 2020 Genitourinary Cancers Symposium!

We have recapped some of the top news presented each day during the meeting—and soon we’ll speak with Dr Daniel Petrylak on the key studies in bladder cancer and prostate cancer, as well as Dr Brian Rini on the latest in kidney cancer.

Welcome to OncLive News Network! I’m Gina Columbus.

In advanced clear cell renal cell carcinoma, the oral HIF-2 alpha inhibitor MK-6482 demonstrated promising clinical activity in heavily pretreated patients in a phase I/II trial.

Results showed that the objective response rate with MK-6482 was 24%, with 69% of patients experiencing tumor shrinkage. Moreover, the median progression-free survival was 11.0 months. The agent was also found to be well tolerated. Based on these encouraging data, there are plans to launch a phase III trial with MK-6482.

The combination of the RTK inhibitor sitravatinib and nivolumab showed a benefit in patients with advanced clear cell renal cell carcinoma following progression on prior VEGF-targeted therapy.

Specifically, results showed that there were higher objective responses and longer disease control versus what is historically expected with single-agent nivolumab in this patient population.

The first results of the phase II NIVES trial showed that nivolumab in combination with stereotactic body radiotherapy led to a high disease control rate in pretreated patients with metastatic renal cell carcinoma.

The regimen also led to no added toxicity, and an analysis is ongoing to explore the correlation between efficacy of the combination and PD-L1 expression.

Real-world results of the Meet-Uro 7 study showed that following progression on immunotherapy, most patients were treated with VEGF-TKI therapy and mTOR inhibitors, which were found to be both active and safe. Specifically, the multikinase TKI cabozantinib was found to be associated with a longer modified progression-free survival.

In the retrospective study, investigators evaluated outcome data, including PFS and toxicities, from 162 eligible patients who were treated across 16 Italian referral centers.

Forty-two month follow-up of the phase III CheckMate-214 trial showed that the combination of nivolumab and ipilimumab showed superior objective response rates and overall survival compared with sunitinib in both intent-to-treat and intermediate and poor-risk patients with advanced renal cell carcinoma.

Additionally, more patients who were treated with nivolumab and ipilimumab experienced a complete response versus sunitinib. Based on earlier data from the CheckMate-214 trial, the FDA approved this combination in April 2018 for intermediate- and poor-risk patients with advanced renal cell carcinoma.

That’s all for today. Thank you for watching OncLive News Network: On Location at the 2020 Genitourinary Cancers Symposium.

Signing off from San Francisco, California, I’m Gina Columbus.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x